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Abstract 
Vitamin D receptor (VDR) mediates the antitumoral action of the active vitamin D metabolite 1 ,25-
dihydroxyvitamin D3 (1,25(OH)2D3). However, VDR expression is lost during colon cancer progression, 
possibly causing unresponsiveness to 1,25(OH)2D3. Although several mechanisms responsible for resistance to 
1,25(OH)2D3 action in different types of cancer had been reported, none explained the loss of VDR expression. 
We have found that the transcription factors Snail1 and Snail2, known as inducers of epithelial-to-
mesenchymal transition (EMT), inhibit VDR expression and block 1,25(OH)2D3 action in colon cancer cells. 
Snail1 and Snail2 have an additive repressing effect on VDR gene promoter. These effects are specific to the 
Snail family, as other transcriptions factors that function as EMT inducers do not inhibit VDR expression in 
colon cancer cells. Moreover, we also found that the RNA expression of SNAI1 and SNAI2 are upregulated in 
human colorectal tumors and inversely correlate with that of VDR. Our results suggest that high levels of 
SNAIL1 and SNAIL2 are a probable cause of VDR downregulation and 1,25(OH)2D3 unresponsiveness in 
colon cancer. In addition, they may contribute to the improvement of protocols for the clinical use of vitamin D 
compounds, as they indicate that advanced colon cancer patients overexpressing SNAIL1 and SNAIL2 are not 
suitable candidates for this therapy. 
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1. Introduction 
1 ,25-dihydroxyvitamin D3 (1,25(OH)2D3) and a number of less calcemic analogs are in clinical trials as 
anticancer agents against colon cancer and other neoplasias based on their antiproliferative, prodifferentiation, 
pro-apoptotic and antimetastatic activity in cultured cells and experimental animal models [1,2]. We have 
shown that 1,25(OH)2D3 inhibits proliferation and promotes differentiation of human colon cancer cells via the 
induction of several genes such the invasion suppressor CDH1/E-cadherin and the candidate tumor suppressor 
CST5/cystatin D, and by the antagonism of the Wnt/ -catenin pathway that is aberrantly activated in most 
colon tumors [3-5]. 
Although preclinical studies are promising, initial clinical trials in colon cancer have shown acceptable 
toxicity but low activity of vitamin D compounds [1]. As is usual in the development of new antitumoral drugs, 
patients enrolled in these trials had not responded to any other therapy and they were unselected in terms of 
putative responsiveness to 1,25(OH)2D3. A better understanding of the physiology of the vitamin D system and 
the identification of the mechanisms responsible for resistance to 1,25(OH)2D3 may help us to design future 
clinical trials more rationally. 
 
2. Vitamin D receptor is downregulated during colon cancer progression 
Most, if not all, 1,25(OH)2D3 effects are mediated by the vitamin D receptor (VDR), a transcription factor 
of the nuclear receptor superfamily. Thus, cellular VDR expression is required for a clinical response to 
vitamin D compounds. VDR is expressed in normal colon epithelial cells and also in some colon cancer cells. 
Remarkably, elevated VDR expression is associated with high differentiation, absence of node involvement 
and favourable prognosis in colorectal cancer [6,7]. However, VDR expression is downregulated during colon 
cancer progression [8-10] probably causing 1,25(OH)2D3 unresponsiveness. 
Although VDR downregulation in colon cancer was first described more than a decade ago, its molecular 
basis had remained elusive. Deletions, rearrangements or point mutations affecting the coding region of the 
VDR gene had not been found in cancer. Neither had epigenetic silencing or transcriptional repression 
mechanisms been described. Several polymorphisms had been described in the VDR gene, some of which have 
been associated with increased risk of breast, prostate and colon cancer. However, their consequences for VDR 
expression or functionality, and therefore their implication in the development of 1,25(OH)2D3 resistance 
remain to be established [11,12]. 
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3. The transcription factors Snail1 and Snail2 repress VDR expression in colon cancer cells 
A novel mechanism responsible for VDR downregulation in colon cancer has emerged in recent years. Our 
group has revealed that the transcription factors Snail1 and Snail2 (also known as Snail and Slug) encoded by 
Snai1 and Snai2 genes, respectively, bind to the promoter region of exon 1a of human VDR gene and repress its 
expression. The repressive effects of Snail1 and Snail2 on VDR gene promoter are quantitatively similar and 
are mediated by three E-boxes (CAGGTG/CACCTG, reported binding sites for Snail factors) present in the 
first 400 nucleotides of human VDR promoter. In addition, we found that both transcription factors cooperate to 
repress VDR promoter, showing an additive effect [13,14]. 
We also found that the overexpression (by means of retrovirus-mediated gene transfer) of Snail1 or Snail2 
in human colon cancer cells decreases VDR RNA and protein expression and strongly inhibits the regulation of 
1,25(OH)2D3 target genes such as CDH1/E-cadherin, p21
CIP1
 and CYP24A1/1,25(OH)2D3-24-hydroxylase. 
Accordingly, Snail transcription factors block the epithelial differentiation induced by 1,25(OH)2D3 in colon 
cancer cells (Fig. 1) and also the inhibitory effect of 1,25(OH)2D3 on Wnt/ -catenin signaling pathway [13-15]. 
 
4. Relevance of VDR downregulation for the epithelial-to-mesenchymal transition induced by Snail1 and 
Snail2 
Snail1 and Snail2 belong to the Snail family of zinc-finger transcription factors and modulate processes 
that imply cell movement during embryonic development and tumor progression. Cellular overexpression of 
Snail1 or Snail2 induces the epithelial-to-mesenchymal transition (EMT), which entails the loss of epithelial 
characteristics and the acquisition of a mesenchymal fibroblastic phenotype [16,17]. Therefore, the expression 
of Snail1 or Snail2 in carcinoma cells promotes their migratory and invasive properties favoring tumor invasion 
and metastasis. Accordingly, the aberrant overexpression of SNAIL1 and/or SNAIL2 has been observed in 
different types of carcinomas and is frequently associated with invasiveness, metastasis and poor prognosis 
[16,17]. 
EMT induction is not an exclusive effect of Snail factors. Other transcriptional regulators such as E47, 
Twist1 and E2-2 (members of the basic-helix-loop-helix family), and Zeb1 and Zeb2 (of the Zeb family) also 
promote this process. EMT is mainly the result of transcriptional changes induced by these factors such as the 
repression of CDH1/E-cadherin, OCLN/occludin, several claudins and other epithelial genes and the induction 
of mesenchymal genes such as FN1/fibronectin, VIM/vimentin, LEF1 and numerous matrix metalloproteases 
[16,17]. 
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As ligand-activated VDR induces epithelial differentiation and the expression of CDH1/E-cadherin and 
other intercellular adhesion genes, VDR repression by Snail1 and Snail2 guarantees the induction of EMT even 
in the presence of 1,25(OH)2D3. This effect seems to be specific to the Snail family of transcription factors, 
since other EMT inducers such as Zeb1, Zeb2, E47 and Twist1 do not inhibit human VDR gene promoter [14]. 
 
5. Snail1 and Snail2 are responsible for VDR downregulation in colon cancer 
To confirm the importance of Snail transcription factors in VDR downregulation during colon cancer 
progression, we analyzed SNAI1, SNAI2 and VDR RNA expression in normal and tumoral biopsies from 
approximately one hundred colon cancer patients. We found that SNAI1 RNA was not present in any normal 
colonic tissue but it was expressed in 60-70% (depending on the study) of colon tumors. VDR expression in 
tumors was reduced with respect to that detected in the corresponding normal tissue in a similar percentage of 
tumors. In contrast, basal SNAI2 RNA expression was detected in most normal tissues and was also upregulated 
in 60% of colon tumors. Importantly, we observed that the overexpression of either SNAI1 or SNAI2 in 
individual tumors correlates with VDR downregulation [13,14,18,19]. In addition, we found that SNAI1 and 
SNAI2 RNA expression correlate directly and, therefore, a high percentage of tumors (42%) express both 
transcription factors. Remarkably, VDR downregulation was stronger in the tumors that express both SNAI1 and 
SNAI2 than in those that express only one of these genes. This is consistent with the additive effect exerted by 
Snail1 and Snail2 on VDR gene promoter in cultured human colon cancer cells [14]. Therefore, it seems that 
Snail1 and Snail2 collaborate in the repression of VDR gene in human colon cancer. 
Based on the hypothesis that tumors cells can influence adjacent normal cells and that some genetic 
alterations occur before the development of histologically abnormal tissue, we have recently expanded our 
studies to analyze the effect of tumoral SNAI1 overexpression on the levels of VDR in the histologically normal 
colonic tissue adjacent to the tumor. We have found that tumoral SNAI1 overexpression correlates with VDR 
downregulation both in the tumor and in the normal adjacent tissue, indicating that SNAIL1 induce the release 
of paracrine signals from the tumoral cells that affect adjacent normal cells [20]. This could extend the 
unresponsiveness to vitamin D compounds to the normal tissue surrounding the tumor. 
The repression of VDR by Snail transcription factors is not exclusive to colon cancer, as it has also been 
observed in human breast cancer cells (ref. 21 and unpublished results). Also, Snail1 inhibits VDR expression 
in mouse osteoblasts [22]. As SNAIL1 and/or SNAIL2 upregulation has been reported in several types of 
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cancer [16], this mechanism could explain the resistance to 1,25(OH)2D3 action due to the VDR repression 
found in other types of tumors [10]. 
 
6. Conclusion 
Our studies indicate that the transcription factors Snail1 and Snail2 are repressors of VDR and thus of 
1,25(OH)2D3 action in colon cancer cells (Fig. 2). Data from colon cancer biopsies indicate that SNAIL1 and 
SNAIL2 may be responsible for VDR downregulation during colon cancer progression. 
Colon cancer patients with high levels of SNAIL1 and SNAIL2 have lower VDR expression and, 
therefore, will be resistant to a therapy with vitamin D compounds. Thus, tumor expression of SNAIL1 and 
SNAIL2 may be used as an indicator of patient adequacy to this treatment. Several groups have detected tumor-
associated RNA in the serum/plasma of cancer patients [23]. If tumor overexpression of SNAI1 and SNAI2 
could be monitored by RT-PCR analysis of the RNA present in the serum/plasma, it would constitute a non-
invasive method to select suitable patients for therapy with vitamin D compounds. 
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Figure Captions 
Fig. 1. The overexpression of Snail1 or Snail2 blocks the acquisition of the epithelial differentiated phenotype 
induced by 1,25(OH)2D3 in SW480-ADH human colon cancer cells. Representative phase-contrast images 
(upper panels) and confocal laser immunofluorescence images showing -tubulin staining (lower panels) of 
Mock, Snail1- and Snail2-overexpressing SW480-ADH cells treated with 100 nM 1,25(OH)2D3 or vehicle for 
48 h. Scale bar, 25 m (upper panels) and 10 m (lower panels). 
 
Fig. 2. Scheme showing the repression of VDR and thereby of 1,25(OH)2D3 action during the EMT induced by 
Snail1 or Snail2. Normal colon epithelial cells express VDR and are responsive to 1,25(OH)2D3 target genes 
induction and antitumoral activity. Snail1 and/or Snail2 overexpression induce EMT through the regulation of 
several target genes. Among them, Snail factors bind to three E-boxes present in human VDR gene promoter 
and inhibit its expression, thus blocking 1,25(OH)2D3 action. 
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